Amgen Wins Legal Round: Amgen Inc. said...
- Share via
Amgen Wins Legal Round: Amgen Inc. said a federal appeals court agreed to temporarily stay a lower court order that called for the Thousand Oaks biotechnology company and Genetics Institute, its rival, to share the market for a lucrative anti-anemia drug called erythropoietin, or EPO. A federal judge in Boston last month ordered Amgen to present a plan by today for the companies to share the market. But Amgen appealed that order, and the deadline was subsequently postponed by the appellate court action.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
